Finch Therapeutics Group 8/10/2023 Earnings Report

Finch Therapeutics Group EPS Results

• Actual EPS: -$4.33
• Consensus EPS: -$4.51
• Beat/Miss: Beat by +$0.18
• One Year Ago EPS: N/A

Finch Therapeutics Group Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Finch Therapeutics Group Announcement Details

• Date: 8/10/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Finch Therapeutics Group (NASDAQ:FNCH) is a clinical-stage biopharmaceutical company developing microbiome-based therapies aimed at treating diseases driven by gut dysbiosis. The company applies a data-driven approach to identify key microbial strains and restore healthy gut function through its proprietary microbial consortia platform. Its lead investigational therapy, RBX2660, is an investigational oral microbiota suspension being evaluated for the prevention of recurrent Clostridioides difficile infection (rCDI).

In addition to RBX2660, Finch is advancing a pipeline of microbiome restoration candidates targeting gastrointestinal and immune-mediated disorders. The company’s technology leverages high-resolution microbial profiling, bioinformatics and manufacturing processes designed to deliver defined biological communities. Early-stage programs include treatments for ulcerative colitis, Crohn’s disease and neurodevelopmental conditions linked to microbiome imbalances.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Finch Therapeutics collaborates with academic institutions, patient advocacy groups and strategic partners to accelerate microbiome therapy development. The organization’s multidisciplinary leadership team brings expertise in microbial ecology, translational medicine and commercial operations. While primarily focused on the U.S. market, Finch has established global research collaborations to explore broader clinical applications of its platform technologies.